TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Travere Therapeutics Inc (TVTX) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA approval of Filspari, which positions it as the only approved treatment for focal segmental glomerulosclerosis (FSGS), a significant market opportunity. Despite insider selling and a decline in net income, the company's revenue growth, bullish technical indicators, and positive analyst sentiment make it a compelling long-term investment.
The stock shows bullish technical indicators with MACD above zero and positively contracting, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a pre-market price increase of 2.28%. RSI is neutral at 68.36, and the stock is trading near its resistance level of 42.372, indicating potential for further upside.
FDA approval of Filspari, the first and only approved treatment for FSGS, significantly expands the addressable market.
Strong revenue growth of 73.41% YoY in Q4
Positive analyst sentiment with multiple price target upgrades and Buy ratings, with targets as high as $
Filspari's demonstrated 46% reduction in proteinuria in a phase 3 study, showcasing its therapeutic advantage.
Insider selling has increased significantly (3880.14% in the last month).
Net income and EPS have declined sharply (-104.53% and -104.17% YoY, respectively).
High implied volatility (45.78%) and low IV percentile (2.79%) suggest uncertainty in the options market.
In Q4 2025, the company reported a 73.41% YoY increase in revenue to $129.69M, driven by strong product performance. However, net income dropped by 104.53% YoY to $2.73M, and EPS fell by 104.17% YoY to $0.03. Gross margin improved slightly to 98.03%, up 1.49% YoY.
Analysts are overwhelmingly positive, with multiple upgrades and price target increases following FDA approval of Filspari. The highest price target is $56, and the consensus sentiment is Buy. Analysts highlight the unmet need in FSGS and expect rapid adoption of Filspari.
